GCG and type 2 diabetes mellitus: In humans, subcutaneous administration of recombinant IL-6 induces dose-dependent increase in fasting blood glucose in healthy people, probably by stimulating glucagon release and/or by inducing peripheral insulin resistance (162), whereas IL-6 blockade improves glycated hemoglobin A1c (HbA1c) in people with T2D (163).